Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Debates on Yearly NHI Price Cuts Put on Hold as Attention Turns to Election
November 26, 2014
- Chuikyo OKs Requirements for Hospitals Offering Mixed Care in Economic Zones
November 25, 2014
- MHLW Designates 6 APIs as Orphan Drugs
November 25, 2014
- PAFSC First Committee Backs Approval of Takeda’s Vonoprazan
November 25, 2014
- IGDRP to Extend Activities for 2 More Years with Aim of Harmonizing Generic Drug Review
November 25, 2014
- MHLW Orders Revision of Package Insert for Reminyl
November 25, 2014
- MHLW Issues Notification on Infection Risk Reporting for Regenerative Medicines
November 21, 2014
- Potential Risk of Narcolepsy for Belsomra Should Be Thoroughly Communicated: Chuikyo
November 21, 2014
- Don’t Use Long-Listed Drugs, Dispense Generics: LDP Project Team
November 21, 2014
- Chuikyo OKs NHI Price Listing of 14 APIs/15 Products
November 20, 2014
- MHLW Will Rack Its Brain about How to Eke Out Social Security Funds: Shiozaki
November 20, 2014
- 3 Straight Years of NHI Price Cuts Loom as Abe Delays Sales Tax Hike, Eyes Now Turned to 2019 and Beyond
November 19, 2014
- MHLW OKs 4 Products Including New Indication for Spiriva
November 19, 2014
- Health Ministry Drug Evaluation Head Calls for Mulling Necessity of PI Studies for Japanese Patients
November 18, 2014
- Only Advantage of Authorized Generics is that “They Can Be Sold Earlier”: Prof. Ogata
November 18, 2014
- PAFSC 2nd Committee to Discuss Novartis’s Secukinumab on Nov. 28
November 18, 2014
- Editor’s Pick: Five Healthcare News Headlines for Nov. 4 - 14
November 17, 2014
- MHLW Official Says Penalty Rule Needs Review, Frowns on Sanguine Outlook for Annual Drug Price Cut
November 17, 2014
- PMDA to Accept All Requests for Generic Drug Face-to-Face Consultations
November 17, 2014
- MHLW to Report Poteligeo’s Additional Indication of Untreated CCR4-Positive ATL to PAFSC 2nd Committee on Nov. 28
November 17, 2014
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…